NEWRON PHARMACEUTICALS SPA

[Available On-Demand]
Newron is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union and Switzerland (both 2015) as well as in the U.S. (2017) and is commercialized in Europe by Newron’s Partner Zambon.Meiji Seika, in collaboration with Eisai, has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition,Newron has a strong pipeline of promising treatments including Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia and ralfinamide for patients with specific rare pain indications. Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA.
Ticker:
NWRN; NP5
Exchange:
SIX; XETRA
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Italy
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
evenamide
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO, Managing Director
Newron Pharmaceuticals SpA